Targeted drug trial aims to slow advanced cancers by blocking key mutation
NCT ID NCT06303167
Summary
This trial is testing whether the drug osimertinib can help control advanced cancers that have specific changes (mutations) in a gene called EGFR. The drug works by blocking the faulty protein these mutations create, which may slow or stop cancer growth. The study is for adults with various advanced or hard-to-treat cancers, including solid tumors, lymphoma, or multiple myeloma, whose tumors have one of these specific EGFR mutations.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.